FDA Approves Belzutifan Plus Lenvatinib for Previously Treated Advanced Clear Cell Renal Cell Carcinoma

As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved the oral combination of belzutifan (Welireg) and lenvatinib (Lenvima) for adults with advanced renal cell carcinoma (RCC)…

Continue Reading FDA Approves Belzutifan Plus Lenvatinib for Previously Treated Advanced Clear Cell Renal Cell Carcinoma

A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

RASONQUE Represents a Watershed Moment for a Disease That Has Resisted Treatment Since RAS Was Discovered as a Cancer-Causing Gene Pancreatic cancer is among the cruelest malignancies. It develops silently,…

Continue Reading A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC

As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…

Continue Reading FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC

New Immunotherapy Strategy Targets Tumor ‘Bodyguards,’ Shows Powerful Results in Preclinical Cancer Models

As reported on ScienceDaily, a research team at the Icahn School of Medicine at Mount Sinai has unveiled a novel immunotherapy that tackles metastatic cancer by attacking the tumor’s protective…

Continue Reading New Immunotherapy Strategy Targets Tumor ‘Bodyguards,’ Shows Powerful Results in Preclinical Cancer Models

Phase 2 GLEAM Trial of Zolbetuximab in Pancreatic Cancer Falls Short of Primary Endpoint

Astellas Pharma Inc. has announced that its Phase 2 GLEAM trial evaluating zolbetuximab in combination with gemcitabine plus nab-paclitaxel for metastatic pancreatic adenocarcinoma did not meet its primary endpoint of…

Continue Reading Phase 2 GLEAM Trial of Zolbetuximab in Pancreatic Cancer Falls Short of Primary Endpoint

Dewpoint Therapeutics Secures Series D Funding to Pioneer Novel Gastric Cancer Therapy

Dewpoint Therapeutics, a U.S.-based biotechnology innovator, has announced the successful closure of its Series D financing round. As reported by thepharmaletter, Dewpoint Therapeutics is renowned for its pioneering work in…

Continue Reading Dewpoint Therapeutics Secures Series D Funding to Pioneer Novel Gastric Cancer Therapy